HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by del Zoppo, G. J. Search for Related Content PubMed PubMed Citation Articles by del Zoppo, G. J.

Clinical trials in acute stroke

Why have they not been successful?

From the Department of Molecular and Experimental Medicine, The Scripps Research Institute and the Division of Hematology/Medical Oncology, Scripps Clinic and Research Foundation, La Jolla, CA.

Address correspondence and reprint requests to Dr. Gregory J. del Zoppo, Department of Molecular and Experimental Medicine, Scripps Clinic and Research Foundation, 10550 North Torrey Pines Road, SBR-17, La Jolla, CA 92037.

Abstract.

Modeling of focal cerebral ischemia seeks to understand mechanisms of injury and to test agents as potential stroke therapies. However, modeling has been singularly unpredictable in ischemic cerebrovascular disease for a number of reasons related to the incompletely understood pathophysiology of ischemic stroke and to the characteristics of models prepared to mimic the clinical condition. The development of models of focal cerebral ischemia must take into account known species differences and idiosyncrasies, underlying vascular disease processes, the nature of thrombotic processes, cellular reactivities, the presence of co-stimulation (e.g., inflammation), the characteristics of immunologicals and reporter molecules, the coincident use of other pharmacologic modifiers (e.g., anesthesia), and stress. These elements are also potential contributors to cerebral tissue injury and its assessment but may affect other species differentially. On the other hand, study design issues have been shown to be particularly relevant to limiting development of some agents for clinical stroke treatment. Experience from experimental and clinical work on vascular active approaches (e.g., plasminogen activators) suggests that active dialogue regarding the relationships between clinical outcomes and outcomes in appropriate animal models is necessary. Success appears are likely when the model more closely matches the known human pathophysiology and the interventions applied in the models are definitely characterized in that species. Rather than moving directly to interventional studies in humans, the use of several appropriate animal models is encouraged where those models exist. Where not, careful consideration of study design and the biology of the disorder is a prerequisite.

This article has been cited by other articles:

				S. Baltan, E. F. Besancon, B. Mbow, Z. Ye, M. A. Hamner, and B. R. Ransom White Matter Vulnerability to Ischemic Injury Increases with Age Because of Enhanced Excitotoxicity J. Neurosci., February 6, 2008; 28(6): 1479 - 1489. [Abstract] [Full Text] [PDF]

				K. Kirchhof, T. Welzel, S. Zoubaa, C. Lichy, M. Sikinger, H. L. de Ruiz, and K. Sartor New Method of Embolus Preparation for Standardized Embolic Stroke in Rabbits Stroke, September 1, 2002; 33(9): 2329 - 2333. [Abstract] [Full Text] [PDF]

				P.-E. Chabrier, M. Auguet, B. Spinnewyn, S. Auvin, S. Cornet, C. Demerle-Pallardy, C. Guilmard-Favre, J.-G. Marin, B. Pignol, V. Gillard-Roubert, et al. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: A promising neuroprotective strategy PNAS, September 14, 1999; 96(19): 10824 - 10829. [Abstract] [Full Text] [PDF]